Ticlopidine Hydrochloride

盐酸噻氯匹定

Report date: 2026/03/24 20:00:35
NME

Base Information

Drug NameTiclopidine Hydrochloride
Drug Alias Name氯苄吡啶Ticlopidinum HydrochlorideTiclopidina Hydrochloride氯匹啶盐酸噻氯匹啶 +[18] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPurinergic receptor P2Y12 antagonists
TargetsPurinergic receptor P2Y12
Therapy Area/IndicationsThromboembolismArterial Occlusive DiseasesVasospasm, Intracranial +[6] 
Global Approved IndicationsThromboembolismArterial Occlusive DiseasesVasospasm, Intracranial +[6] 
Approved Indications in ChinaThromboembolism
Original Approved Country/TerritoryN/A
Original Approved Date1978/01/01
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdNichi-Iko Pharmaceutical Co LtdXinxin Pharmaceutical Factory of Tianjin Zhongxin Pharmaceutical Group Co Ltd
Inactive CompaniesRoche Palo Alto Llc
Active IndicationsThromboembolismArterial Occlusive DiseasesVasospasm, Intracranial +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeB01AC05
Related LinksWikipediaDrugBankKEGG